EFTR vs. VCNX, HEPA, CYCN, UPC, KTTA, CANF, BNOX, VIRI, CVKD, and PCSA
Should you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Vaccinex (VCNX), Hepion Pharmaceuticals (HEPA), Cyclerion Therapeutics (CYCN), Universe Pharmaceuticals (UPC), Pasithea Therapeutics (KTTA), Can-Fite BioPharma (CANF), Bionomics (BNOX), Virios Therapeutics (VIRI), Cadrenal Therapeutics (CVKD), and Processa Pharmaceuticals (PCSA). These companies are all part of the "pharmaceutical preparations" industry.
eFFECTOR Therapeutics (NASDAQ:EFTR) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
eFFECTOR Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Vaccinex has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.
In the previous week, eFFECTOR Therapeutics had 4 more articles in the media than Vaccinex. MarketBeat recorded 6 mentions for eFFECTOR Therapeutics and 2 mentions for Vaccinex. eFFECTOR Therapeutics' average media sentiment score of 0.81 beat Vaccinex's score of 0.00 indicating that eFFECTOR Therapeutics is being referred to more favorably in the media.
Vaccinex received 100 more outperform votes than eFFECTOR Therapeutics when rated by MarketBeat users. However, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 60.00% of users gave Vaccinex an outperform vote.
eFFECTOR Therapeutics currently has a consensus target price of $24.00, indicating a potential upside of 1,082.27%. Given eFFECTOR Therapeutics' higher possible upside, analysts clearly believe eFFECTOR Therapeutics is more favorable than Vaccinex.
Vaccinex has lower revenue, but higher earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.
eFFECTOR Therapeutics' return on equity of 0.00% beat Vaccinex's return on equity.
57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 8.4% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
eFFECTOR Therapeutics beats Vaccinex on 11 of the 16 factors compared between the two stocks.
Get eFFECTOR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
eFFECTOR Therapeutics Competitors List
Related Companies and Tools
